Table 4.
Most commonly reported (≥5% in either treatment group) adverse events.
| Bromocriptine-QR N = 1219 |
Placebo N = 615 |
|
|---|---|---|
| N (%) | N (%) | |
| Nausea | 386 (31.7)∗ | 49 (8.0) |
| Dizziness | 189 (15.5)∗ | 53 (8.6) |
| Headache | 141 (11.6) | 54 (8.8) |
| Fatigue | 170 (13.9)∗ | 43 (7.0) |
| Vomiting | 106 (8.7)∗ | 21 (3.4) |
| Constipation | 69 (5.7) | 31 (5.0) |
| Hypoglycemia | 67 (5.5) | 26 (4.2) |
| Diarrhea | 92 (7.5) | 49 (8.0) |
| Nasopharyngitis | 64 (5.3) | 34 (5.5) |
| Upper respiratory infection | 60 (4.9) | 40 (6.5) |
| Arthralgia | 47 (3.8)† | 38 (6.2) |
∗Between-group difference p < 0.0001.
†Between-group difference p = 0.03.